Supplementary Table S3. Adverse events related to MOXR0916 occurring in ≥5 patients overall

MedDRA preferred term, *n* (%)	0.2 to 160 mg *n*=53		300 mg *n*=109		600 mg *n*=6		1200 mg *n*=4		All Patients (*N*=172)	
	Grade		Grade		Grade		Grade		Grade	
	All	≥3	All	≥3	All	≥3	All	≥3	All	≥3
Patients with ≥1 AE	32 (60)	0	60 (55)	0	3 (50)	0	3 (75)	0	98 (57)	7 (4)
Fatigue	10 (19)	0	17 (16)	0	2 (33)	0	1 (25)	0	30 (17)	1 (1)
Diarrhea	7 (13)	0	6 (6)	0	0	0	0	0	13 (8)	0
Myalgia	2 (4)	0	9 (8)	0	1 (17)	0	0	0	12 (7)	0
Nausea	5 (9)	0	6 (6)	0	0	0	0	0	11 (6)	0
Decreased appetite	3 (6)	0	7 (6)	0	0	0	0	0	10 (6)	0
Infusion related reaction	5 (9)	0	3 (3)	0	0	0	1 (25)	0	9 (5)	0
Vomiting	2 (4)	0	6 (6)	0	0	0	0	0	8 (5)	0
Arthralgia	3 (6)	0	4 (4)	0	0	0	0	0	7 (4)	0
Pyrexia	4 (8)	0	3 (3)	0	0	0	0	0	7 (4)	0
Constipation	1 (2)	0	5 (%)	0	0	0	0	0	6 (4)	0
Anemia	2 (4)	0	2 (2)	0	0	0	1 (25)	0	5 (3)	0
Asthenia	1 (2)	0	4 (4)	0	0	0	0	0	5 (3)	0
Chills	2 (4)	0	3 (3)	0	0	0	0	0	5 (3)	0
Headache	1 (2)	0	4 (4)	0	0	0	0	0	5 (3)	0
Rash	1 (2)	0	4 (4)	0	0	0	0	0	5 (3)	0